Developer docs
API playgroundTry for free, no card

Search company profiles

Protembis

Full company profile

uuid0000uj2

Namestring
Protembis
Legal namestring
Protembis GmbH
Websiteurl
protembis.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Protembis is a privately-held medical device company founded in 2013 and headquartered in Aachen, Germany, with a US subsidiary (Protembis, Inc.) established in 2024 in Wilmington, Delaware. The company develops the ProtEmbo Cerebral Protection System (CPS), a third-generation intra-aortic filter designed to shield all three cerebral arteries from embolic debris liberated during transcatheter aortic valve replacement (TAVR) procedures. The device features a 60μm pore filter with covalently bonded heparin coating, is anchored in the left subclavian artery, and is delivered via 6F left radial access with self-positioning design enabling deployment in under 5 minutes. A companion SimplGuide guiding sheath supports device delivery. The company also develops patient and physician educational content around TAVR-related stroke and cognitive decline risk.

Protembis is pre-revenue and has not received regulatory approval for commercial sale in any jurisdiction. It is currently conducting the FDA-approved PROTEMBO IDE Pivotal Trial (NCT05873816) — an adaptive, multicenter, randomized controlled trial enrolling 250-500 TAVR patients across up to 30 sites in the USA, Germany, and Poland, comparing ProtEmbo against a hybrid control of Sentinel CEP and No Device using DW-MRI endpoints. Earlier European studies include PROTEMBO C (64 patients, met safety and performance endpoints with 94% of patients free of clinically meaningful brain lesions >350mm³) and PROTEMBO SF. The company plans to commercialize via direct hospital sales targeting high-volume TAVR centers and academic centers of excellence upon regulatory approval.

Protembis has raised approximately €50 million in total funding: a $10M Series A in October 2018 (Abiomed, Seed Fonds III, Coparion, family offices, angels), a €30M Series B in March 2024 (co-led by Segulah Medical Acceleration, XGEN Venture, TechVision Fund), and €20M in venture debt from the European Investment Bank in July 2024. The company operates with a lean team of approximately 10 employees, co-led by founders Karl von Mangoldt and Conrad Rasmus as Co-CEOs, with a Board chaired by Azin Parhizgar (former Claret Medical CEO). The addressable market is anchored by the global TAVR procedure volume, projected at approximately 430,000 patients by 2025.

Short descriptiontext

Protembis is a pre-revenue German medical device company developing the ProtEmbo Cerebral Protection System, an intra-aortic filter that shields all three cerebral arteries during TAVR procedures. It serves interventional cardiologists and structural heart teams and is currently in FDA-approved pivotal clinical trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAachen, Germany
HQ citystring
Aachen
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cerebral embolic protection, transcatheter aortic valve replacement, intra-aortic filter devices, cardiovascular medical devices, stroke prevention devices
Industry2 codes
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAE
Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code1 code
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Cerebral Embolic Protection Devices
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Protembis is a pre-revenue medical device company developing the ProtEmbo Cerebral Protection System. The product is currently undergoing clinical investigation and has not yet been approved for commercial use by any regulatory authority. Revenue will be generated through device sales to hospitals following regulatory approval.

protembis.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1ProtEmbo
Description

The ProtEmbo Cerebral Protection System (CPS) - an intra-aortic filter device that protects the entire brain from embolic material liberated during transcatheter aortic valve replacement (TAVR) procedures.

protembis.com
+1 more record
Core offering1 text field

Protembis develops the ProtEmbo Cerebral Protection System (CPS), an intra-aortic filter device designed to shield all three cerebral arteries supplying blood to the brain during transcatheter aortic valve replacement (TAVR) procedures. The system is delivered via 6F left radial artery access using a companion SimplGuide guiding sheath, and is intended to capture embolic debris liberated during TAVR to reduce the risk of stroke and cognitive decline. The company also produces the SimplGuide braided guiding sheath used to deliver the ProtEmbo device into the vascular system. Both products are currently under clinical investigation and have not yet received regulatory approval for commercial use.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 10 values shown
  • 94% of patients treated with ProtEmbo were free of clinically meaningful brain lesions >350mm3
+9 more records
Product overview1 text field

Protembis is a cardiovascular medical device company offering two integrated products: the ProtEmbo Cerebral Protection System (CPS) as its primary therapeutic device, and the SimplGuide Guiding Sheath as its companion delivery technology. The ProtEmbo CPS is an intra-aortic filter that provides complete three-vessel cerebral protection during TAVR procedures, while SimplGuide serves as the guiding sheath pathway for device delivery. Both products are designed to work together within the TAVR workflow, with SimplGuide providing the procedural access and ProtEmbo providing the cerebral embolic protection. Both devices are currently under clinical and regulatory evaluation and have not yet been approved for commercial use.

Product and service2 records
1ProtEmbo Cerebral Protection System (CPS)
CategoryCerebral Embolic Protection Devices
Description

The ProtEmbo Cerebral Protection System (CPS) is an intra-aortic filter device that shields all three arteries supplying blood to the brain (brachiocephalic, left common carotid, and left vertebral arteries) during transcatheter aortic valve replacement (TAVR) procedures. It features a 60-micron pore filter with covalently bonded heparin coating, anchors in the left subclavian artery, and is delivered via 6F left radial access in under 5 minutes. It is intended for interventional cardiologists and structural heart teams performing TAVR on patients with severe aortic stenosis.

2SimplGuide Guiding Sheath
CategoryVascular Access Sheaths
Description

SimplGuide is a braided guiding sheath with a radiopaque tip, hydrophilic coating, and superior tensile strength, designed to provide a pathway through which therapeutic and diagnostic devices (including the ProtEmbo CPS) are introduced to the coronary or peripheral vascular system. It is intended for use in catheterization laboratory procedures alongside ProtEmbo deployment. Reference Number: 561913108.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-10-29
Description

Core MRI laboratory partner for the PROTEMBO IDE trial. Provides neuroimaging analysis services for the DW-MRI endpoint assessments.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-10-29
Description

Core angiography laboratory partner for the PROTEMBO IDE trial.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-10-29
Description

Core histopathology laboratory partner for the PROTEMBO IDE trial.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-10-29
Description

Core CT laboratory partner for the PROTEMBO IDE trial.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers8 records
TypeBroad incumbent
Description

Acquired Claret Medical in 2017 for $270M and now markets the Sentinel Cerebral Protection System, the only commercially approved CEP device in TAVR and ProtEmbo's direct head-to-head comparator in the IDE trial. Boston Scientific is the dominant entrenched competitor.

TypeBroad incumbent
Description

Global leader in transcatheter aortic valve replacement (SAPIEN platform) and structural heart. While Edwards does not sell a CEP device, it controls a large share of the TAVR procedures where ProtEmbo would be deployed and could bundle or block access.

TypeBroad incumbent
Description

Major TAVR manufacturer (Evolut platform) and a participant in the broader structural heart and embolic protection landscape. Medtronic is a strategic acquirer profile and a potential channel partner for ProtEmbo adoption.

4Abbott
TypeBroad incumbent
Description

Markets the Navitor TAVR platform and has growing structural heart franchise. As a major TAVR incumbent, Abbott is a relevant peer for procedure economics and potential CEP partnership or competitive response.

TypeEmerging player
Description

Develops embolic prevention and carotid stent products (CGuard). InspireMD overlaps thematically with cerebral and vascular embolic protection but targets different anatomies (carotid vs cerebral).

TypeEmerging player
Description

Developer of neurovascular thrombectomy and aspiration devices. While focused on ischemic stroke intervention post-event, Penumbra is adjacent to the embolic protection space and a potential consolidator of cerebral vascular medtech.

TypeEmerging player
Description

Specialist in venous thromboembolism and mechanical thrombectomy devices. Inari operates adjacent to the embolic protection theme and represents the type of growth-stage acquirer that could pursue complementary technology.

TypeEmerging player
Description

Developer of the Emboliner total embolic protection device for use during TAVR and other structural heart procedures. Emboline is the most direct emerging competitor to ProtEmbo in next-generation cerebral embolic protection.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Protembis

Cerebral Embolic Protection Devicesprotembis.com

Protembis is a pre-revenue German medical device company developing the ProtEmbo Cerebral Protection System, an intra-aortic filter that shields all three cerebral arteries during TAVR procedures. It serves interventional cardiologists and structural heart teams and is currently in FDA-approved pivotal clinical trials.

What Protembis does

Protembis is a privately-held medical device company founded in 2013 and headquartered in Aachen, Germany, with a US subsidiary (Protembis, Inc.) established in 2024 in Wilmington, Delaware. The company develops the ProtEmbo Cerebral Protection System (CPS), a third-generation intra-aortic filter designed to shield all three cerebral arteries from embolic debris liberated during transcatheter aortic valve replacement (TAVR) procedures. The device features a 60μm pore filter with covalently bonded heparin coating, is anchored in the left subclavian artery, and is delivered via 6F left radial access with self-positioning design enabling deployment in under 5 minutes. A companion SimplGuide guiding sheath supports device delivery. The company also develops patient and physician educational content around TAVR-related stroke and cognitive decline risk.

Protembis is pre-revenue and has not received regulatory approval for commercial sale in any jurisdiction. It is currently conducting the FDA-approved PROTEMBO IDE Pivotal Trial (NCT05873816) — an adaptive, multicenter, randomized controlled trial enrolling 250-500 TAVR patients across up to 30 sites in the USA, Germany, and Poland, comparing ProtEmbo against a hybrid control of Sentinel CEP and No Device using DW-MRI endpoints. Earlier European studies include PROTEMBO C (64 patients, met safety and performance endpoints with 94% of patients free of clinically meaningful brain lesions >350mm³) and PROTEMBO SF. The company plans to commercialize via direct hospital sales targeting high-volume TAVR centers and academic centers of excellence upon regulatory approval.

Protembis has raised approximately €50 million in total funding: a $10M Series A in October 2018 (Abiomed, Seed Fonds III, Coparion, family offices, angels), a €30M Series B in March 2024 (co-led by Segulah Medical Acceleration, XGEN Venture, TechVision Fund), and €20M in venture debt from the European Investment Bank in July 2024. The company operates with a lean team of approximately 10 employees, co-led by founders Karl von Mangoldt and Conrad Rasmus as Co-CEOs, with a Board chaired by Azin Parhizgar (former Claret Medical CEO). The addressable market is anchored by the global TAVR procedure volume, projected at approximately 430,000 patients by 2025.

Protembis firmographics

Firmographics
Name
Protembis
Legal name
Protembis GmbH
Website
https://protembis.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Protembis is a pre-revenue German medical device company developing the ProtEmbo Cerebral Protection System, an intra-aortic filter that shields all three cerebral arteries during TAVR procedures. It serves interventional cardiologists and structural heart teams and is currently in FDA-approved pivotal clinical trials.
Ownership category
akta.pro rank

Protembis industry classification

Industry
Product category
Cerebral Embolic Protection Devices
NAICS
Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAE
Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Cerebral embolic protection
  • Transcatheter aortic valve replacement
  • Intra-aortic filter devices
  • Cardiovascular medical devices
  • Stroke prevention devices

Where Protembis is headquartered

Location

Headquarters

HQ city
Aachen
HQ country
Germany
HQ region
Europe

Offices2 records

Markets served

Protembis business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Medical Device Sales: Protembis is a pre-revenue medical device company developing the ProtEmbo Cerebral Protection System. The product is currently undergoing clinical investigation and has not yet been approved for commercial use by any regulatory authority. Revenue will be generated through device sales to hospitals following regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Protembis product offering

Product offering

Core offering

Protembis develops the ProtEmbo Cerebral Protection System (CPS), an intra-aortic filter device designed to shield all three cerebral arteries supplying blood to the brain during transcatheter aortic valve replacement (TAVR) procedures. The system is delivered via 6F left radial artery access using a companion SimplGuide guiding sheath, and is intended to capture embolic debris liberated during TAVR to reduce the risk of stroke and cognitive decline. The company also produces the SimplGuide braided guiding sheath used to deliver the ProtEmbo device into the vascular system. Both products are currently under clinical investigation and have not yet received regulatory approval for commercial use.

Product overview

Protembis is a cardiovascular medical device company offering two integrated products: the ProtEmbo Cerebral Protection System (CPS) as its primary therapeutic device, and the SimplGuide Guiding Sheath as its companion delivery technology. The ProtEmbo CPS is an intra-aortic filter that provides complete three-vessel cerebral protection during TAVR procedures, while SimplGuide serves as the guiding sheath pathway for device delivery. Both products are designed to work together within the TAVR workflow, with SimplGuide providing the procedural access and ProtEmbo providing the cerebral embolic protection. Both devices are currently under clinical and regulatory evaluation and have not yet been approved for commercial use.

Differentiator

Problem solved

Functional benefit

Brands

  • ProtEmbo: The ProtEmbo Cerebral Protection System (CPS) - an intra-aortic filter device that protects the entire brain from embolic material liberated during transcatheter aortic valve replacement (TAVR) procedures.
  • SimplGuide

Products and services

  • ProtEmbo Cerebral Protection System (CPS) The ProtEmbo Cerebral Protection System (CPS) is an intra-aortic filter device that shields all three arteries supplying blood to the brain (brachiocephalic, left common carotid, and left vertebral arteries) during transcatheter aortic valve replacement (TAVR) procedures. It features a 60-micron pore filter with covalently bonded heparin coating, anchors in the left subclavian artery, and is delivered via 6F left radial access in under 5 minutes. It is intended for interventional cardiologists and structural heart teams performing TAVR on patients with severe aortic stenosis.
  • SimplGuide Guiding Sheath SimplGuide is a braided guiding sheath with a radiopaque tip, hydrophilic coating, and superior tensile strength, designed to provide a pathway through which therapeutic and diagnostic devices (including the ProtEmbo CPS) are introduced to the coronary or peripheral vascular system. It is intended for use in catheterization laboratory procedures alongside ProtEmbo deployment. Reference Number: 561913108.

Quantifiable outcome

  • 94% of patients treated with ProtEmbo were free of clinically meaningful brain lesions >350mm3
  • +9 more outcomes

Companies that use Protembis

Customer profile

Segments2 records

Ideal customer profiles1 record

Protembis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Protembis partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Buffalo Neuroimaging Analysis Center (BNAC)coreTechnology or Integration · 29 October 2024Core MRI laboratory partner for the PROTEMBO IDE trial. Provides neuroimaging analysis services for the DW-MRI endpoint assessments.
  • Cardiovascular Research Institute (CRF)coreTechnology or Integration · 29 October 2024Core angiography laboratory partner for the PROTEMBO IDE trial.
  • CVPath InstitutecoreTechnology or Integration · 29 October 2024Core histopathology laboratory partner for the PROTEMBO IDE trial.
  • AngioConsultcoreTechnology or Integration · 29 October 2024Core CT laboratory partner for the PROTEMBO IDE trial.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Protembis competitors and assessment

Company assessment

Broad incumbents

  • Boston Scientific: Acquired Claret Medical in 2017 for $270M and now markets the Sentinel Cerebral Protection System, the only commercially approved CEP device in TAVR and ProtEmbo's direct head-to-head comparator in the IDE trial. Boston Scientific is the dominant entrenched competitor.
  • Edwards Lifesciences: Global leader in transcatheter aortic valve replacement (SAPIEN platform) and structural heart. While Edwards does not sell a CEP device, it controls a large share of the TAVR procedures where ProtEmbo would be deployed and could bundle or block access.
  • Medtronic: Major TAVR manufacturer (Evolut platform) and a participant in the broader structural heart and embolic protection landscape. Medtronic is a strategic acquirer profile and a potential channel partner for ProtEmbo adoption.
  • Abbott: Markets the Navitor TAVR platform and has growing structural heart franchise. As a major TAVR incumbent, Abbott is a relevant peer for procedure economics and potential CEP partnership or competitive response.

Emerging players

  • InspireMD: Develops embolic prevention and carotid stent products (CGuard). InspireMD overlaps thematically with cerebral and vascular embolic protection but targets different anatomies (carotid vs cerebral).
  • Penumbra: Developer of neurovascular thrombectomy and aspiration devices. While focused on ischemic stroke intervention post-event, Penumbra is adjacent to the embolic protection space and a potential consolidator of cerebral vascular medtech.
  • Inari Medical: Specialist in venous thromboembolism and mechanical thrombectomy devices. Inari operates adjacent to the embolic protection theme and represents the type of growth-stage acquirer that could pursue complementary technology.
  • Emboline: Developer of the Emboliner total embolic protection device for use during TAVR and other structural heart procedures. Emboline is the most direct emerging competitor to ProtEmbo in next-generation cerebral embolic protection.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Protembis social profiles

Digital presence

Protembis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Protembis leadership team

Management profile

Number of profiles

Profiles10 records

Protembis subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Protembis funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Protembis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Protembis

What does Protembis do?

Protembis develops the ProtEmbo Cerebral Protection System (CPS), an intra-aortic filter device designed to shield all three cerebral arteries supplying blood to the brain during transcatheter aortic valve replacement (TAVR) procedures. The system is delivered via 6F left radial artery access using a companion SimplGuide guiding sheath, and is intended to capture embolic debris liberated during TAVR to reduce the risk of stroke and cognitive decline. The company also produces the SimplGuide braided guiding sheath used to deliver the ProtEmbo device into the vascular system. Both products are currently under clinical investigation and have not yet received regulatory approval for commercial use.

Is Protembis a public or private company?

Protembis is a private company. It is classified as venture growth investor backed and is currently operating.

When was Protembis founded?

Protembis was founded in 2013. It employs 11 to 50 people.

Where is Protembis based?

Protembis is headquartered in Aachen, Germany, in the Europe region.

How does Protembis make money?

One revenue line is on record: medical Device Sales.

Who are Protembis's main competitors?

Broad incumbents on record are Boston Scientific, Edwards Lifesciences, Medtronic and Abbott. Emerging players are InspireMD, Penumbra, Inari Medical and Emboline.

Does Protembis have an API?

No public API is recorded for Protembis.

What industry is Protembis in?

Protembis's product category is Cerebral Embolic Protection Devices. Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices, with a secondary code of HLAHAFAE, Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy). Its NAICS code is 33451 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Tech Funding NewsEIB invests €20M in Protembis, a German startup that develops brain protection device — TFNGerman medical technology company Protembis has secured €20 million in venture-debt financing from the European Investment Bank (EIB) to develop its ProtEmbo cerebral embolic protection system. The device is designed to protect patients' brains from stroke risks during transcatheter aortic valve replacement procedures. This funding supports clinical trials, research, and market access for the technology.FinSMEsProtembis Receives €20M in Venture Financing From EIBProtembis, a German medical-technology firm, received €20M in venture-debt financing from the European Investment Bank. The company will use the funds to complete clinical trials and support marketing of its ProtEmbo cerebral embolic protection system. It previously completed a €30M Series B in March 2024.EibGermany: Medtech Protembis gets €20 million EIB backing for technology to protect brain during heart treatmentThe European Investment Bank (EIB) is providing €20 million in venture-debt financing to German medtech company Protembis to support the clinical trials and market access of its ProtEmbo cerebral embolic protection system. This funding will accelerate research and development for a device designed to prevent brain injury during transcatheter aortic valve replacement (TAVR) procedures in Europe, the US, and other regions.EuropaWireEIB Provides Venture Debt to Protembis for Advanced Brain Protection Technology in Heart TreatmentsThe European Investment Bank (EIB) has provided €20 million in venture debt financing to German medical technology company Protembis. The funds will support the development, clinical trials, and market access of ProtEmbo, a cerebral embolic protection system designed to reduce stroke risk during heart procedures like TAVR.MassDeviceProtembis raises $21.6M for brain protection deviceProtembis secured $21.6 million in venture-debt financing from the European Investment Bank (EIB) to support the development of its ProtEmbo brain protection device for TAVR procedures. This funding builds upon a previous Series B round and is backed by the InvestEU program, which aims to mobilize additional investment in new technologies.Pulse 2.0Protembis: Cardiovascular Medical Device Company Raises €30 MillionProtembis completed a €30 million Series B funding round to support enrollment in its PROTEMBO IDE pivotal trial. The round was co-led by a European VC consortium, and the company added Dr. Keith D. Dawkins to its board. The funding aims to advance cerebral embolic protection for transcatheter aortic valve replacement.FinSMEsProtembis Closes € 30M Series B FinancingProtembis, a German cardiovascular device company, raised €30M in Series B funding led by Segulah Medical Acceleration, XGEN Venture, and TechVision Fund. The company will use the funds to support enrollment in the ProtEmbo Investigational Device Exemption Pivotal Trial. The ProtEmbo Cerebral Protection System is currently undergoing clinical investigations.Tech.euProtembis raise €30M Series B for heart surgery deviceMedtech company Protembis has raised a €30M Series B funding round to support clinical trials for its PROTEMBO investigational device, which protects patients from brain injury during heart surgery. The investment was co-led by a European consortium of venture capital firms including Segulah Medical Acceleration, XGEN Venture, and TechVision Fund. Additionally, the company appointed Dr. Keith D. Dawkins to its board of directors to guide the development of its cerebral embolic protection technology.MassDeviceProtembis raises $32.6M, adds Shockwave exec to boardProtembis, a cardiovascular medical device maker based in Aachen, Germany, completed a $32.6 million Series B financing round led by European VC investors including Segulah Medical Acceleration and XGEN Venture. The company intends to use the capital to support enrollment for its PROTEMBO FDA investigational device exemption trial evaluating its embolic protection technology. Additionally, Protembis appointed Dr. Keith D. Dawkins, currently chief medical officer at Shockwave Medical, to its board of directors.